All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Mirobio Ltd. is poised to take two checkpoint agonists into the clinic in the treatment of autoimmune diseases, after closing a $97 million series B round. The most advanced program, MB-272, is an agonist of the B and T lymphocyte attenuator receptor that relays inhibitory signals to suppress the immune response. Mirobio says activating it has a “far reaching” regulatory effect, restoring self-tolerance across several major autoimmune diseases, including lupus.
Investors are backing imaging diagnostics company Magnetic Insight Inc. with $17 million to develop its magnetic particle imaging (MPI) technology. The clinical imaging application consists of two core technologies: hardware and a tracer that, together, produce 3D images of how a patient’s body works. Venture firm Celesta Capital led the series B round with Alumni Ventures Group, Gaingels and existing investors 5AM Ventures and Sand Hill Angels participating.